Galecto Appoints Anne Prener to its Board of Directors
BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) — Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of
Read moreNasdaq:GLTO
Galecto to Take Part in Two Panel Discussions at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development
Read moreGalecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing Marked Impact on Several IPF Biomarkers
The ERJ Paper shows major effects on biomarkers in IPF, linked to mortality and to fall in FVC The inhaled
Read moreGalecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing Marked Impact on Several IPF Biomarkers
The ERJ Paper shows major effects on biomarkers in IPF, linked to mortality and to fall in FVC The inhaled
Read moreGalecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors
Has extensive experience in pharma and biotech in U.S., Europe and globally Galecto completed U.S. initial public offering and plans
Read moreGalecto Announces Pricing of Initial Public Offering
BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics
Read more